Clinical & Experimental Metastasis

, Volume 7, Issue 3, pp 329–341 | Cite as

Changes in the tumorigenic and metastatic properties of murine melanoma cells treated with a triazene derivative

  • M. Allegrucci
  • P. Fuschiotti
  • P. Puccetti
  • L. Romani
  • M. C. Fioretti
Article

Abstract

Treatment of B16/BL6 murine melanoma cellsin vitro with the ‘xenogenizing’ agent potassiump-(3-methyl-1-triazeno)benzoate (MM-COOK) had a profound impact on the tumorigenic and metastatic properties of the tumor, an effect that was only detectable in immunologically intact hosts. The treated tumor cells gave rise to a considerably smaller number of experimental and spontaneous pulmonary metastases and displayed an impaired growth ratein vivo, but were highly tumorigenic and metastatic in irradiated recipients. Moreover, the drug-treated cells retained thein vitro growth pattern and plating efficiency of the parent line, and were able actively to immunize intact hosts. Studies aimed at clarifying the mechanisms responsible for the decreased metastatic potential of the cells treated with MM-COOK indicated the involvement of host immune responses largely mediated by cells in the T-dependent compartment with no major contribution of natural immunity effector mechanisms.

Keywords

Melanoma Cell Parent Line Pulmonary Metastasis Host Immune Response Profound Impact 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Allison, A. C., 1976, Fluorescence microscopy of lymphocytes and mononuclear phagocytes and the use of silica to eliminate the latter.In Vitro Methods in Cell-Mediated and Tumor Immunity, edited by B. R. Bloom and J. R. David (New York: Academic Press), pp. 395–403.Google Scholar
  2. [2]
    Bianchi, R., Romani, L., Puccetti, P., andFioretti, M. C., 1987, Inhibition of murine lymphoma growth by adoptive transfer of lymphocytes sensitized to a xenogenized tumor variant.International Journal of Cancer,40, 7–11.Google Scholar
  3. [3]
    Boon, T., 1983, Antigenic tumor cell variants obtained with mutagens.Advances in Cancer Research,39, 121–151.Google Scholar
  4. [4]
    Borel, J. F., Feurer, C., Gubler, H. U., andStahelin, H., 1976, Biological effects of cyclosporin A: a new antilymphocytic agent.Agents and Actions,6, 468–475.Google Scholar
  5. [5]
    Borel, J. F., Feurer, C., Magnée, C., andStahelin, H., 1977, Effects of the new anti-lymphocytic peptide cyclosporin A in animals.Immunology,32, 1017–1025.Google Scholar
  6. [6]
    Fioretti, M. C., Nardelli, B., Bianchi, R., Nisi, C., andSava, G., 1981, Antigenic changes of a murine lymphoma by in vivo treatment with triazeme derivatives.Cancer Immunology Immunotherapy,11, 283–286.Google Scholar
  7. [7]
    Flateau, E., Bogenmann, E., andJones, P. A., 1983, Variable 5-methylcytosine levels in human tumor cell lines and fresh pediatric explants.Cancer Research,43, 4901–4904.Google Scholar
  8. [8]
    Frost, P., Liteplo, R. B., Donaghue, T. P., andKerbel, P. S., 1984, Selection of strongly immunogenic “tum” variants from tumors at high frequency using 5-azacytidine.Journal of Experimental Medicine,159, 1491–1501.Google Scholar
  9. [9]
    Giampietri, A., Bonmassar, A., Puccetti, P., Circolo, A., Goldin, A., andBonmassar, E., 1981, Drug-mediated increase of tumor immunogenicity in vivo for a new approach to experimental cancer immunotherapy.Cancer Research,41, 681–687.Google Scholar
  10. [10]
    Giraldi, T., andSava, G., 1981, Selective antimetastatic drugs.Anticancer Research,1, 163–174.Google Scholar
  11. [11]
    Gorelik, E., 1983, Concomitant tumor immunity and the resistance to a second tumor challenge.Advances in Cancer Research,39, 71–120.Google Scholar
  12. [12]
    Gorelik, E., 1985, H-2 expression, immunogenicity and metastatic properties of BL6 melanoma cells treated with MNNG.Treatment of Metastasis: Problems and Prospects Proceedings, edited by K. Hellmann and S. A. Eccles (Philadelphia: Taylor & Francis), pp. 355–359.Google Scholar
  13. [13]
    Hart, I. R., 1979, Selection and characterization of an invasive variant of the B16 melanoma.American Journal of Pathology,97, 587–600.Google Scholar
  14. [14]
    Ishikawa, M., Okada, F., Hamada, J., Hosokawa, M., andKobayashi, H., 1987, Changes in the tumorigenic and metastatic properties of tumor cells treated with quercitin or 5-azacytidine.International Journal of Cancer,39, 338–342.Google Scholar
  15. [15]
    Kerbel, R. S., Frost, P., Liteplo, R. B., Carlow, D. A., andElliott, B. E., 1984, Possible epigenetic mechanisms of tumor progression: induction of high frequency heritable but phenotypically unstable changes in the tumorigenic and metastatic properties of tumor-cell populations by 5-azacytidine treatment.Journal of Cell Physiology,3, 87–97.Google Scholar
  16. [16]
    Nardelli, B., Contessa, A. R., Romani, L., Sava, G., Nisi, C., andFioretti, M. C., 1984, Immunogenic changes of murine lymphoma cells following in vitro treatment with aryl-triazene derivatives.Cancer Immunology Immunotherapy,16, 157–161.Google Scholar
  17. [17]
    Nardelli, B., Puccetti, P., Romani, L., Sava, G., Bonmassar, E., andFioretti, M. C., 1984, Chemical xenogenization of murine lymphoma cells with triazene derivatives: immunotoxicological studies.Cancer Immunology Immunotherapy,17, 213–217.Google Scholar
  18. [18]
    Puccetti, P., Fuschiotti, P., Dominici, P., Borri-Voltattorni, C., Romani, L., andFioretti, M. C., 1987, DNA methylating activity in murine lymphoma cells xenogenized by triazene derivatives.International Journal of Cancer,39, 769–773.Google Scholar
  19. [19]
    Puccetti, P., Romani, L., andFioretti, M. C., 1987, Chemical xenogenization of experimental tumors.Cancer Metastasis Reviews,6, 93–111.Google Scholar
  20. [20]
    Riccardi, C., Puccetti, P., Santoni, A., Herberman, P. B., 1979, Rapid in vivo assay of mouse natural killer cell activity.Journal of National Cancer Institute,63, 1041–1045.Google Scholar
  21. [21]
    Riccardi, C., Santoni, A., Barlozzari, T., Puccetti, P., andHerberman, R. B., 1980, In vivo natural reactivity of mice against tumor cells.International Journal of Cancer,25, 475–486.Google Scholar
  22. [22]
    Romani, L., Bianchi, R., Puccetti, P., andFioretti, M. C., 1983, Systemic adoptive immunotherapy of a highly immunogenic murine lymphoma growing in the brain.International Journal on Cancer,31, 477–482.Google Scholar
  23. [23]
    Romani, L., Fioretti, M. C., Bianchi, R., Nardelli, B., andBonmassar, E., 1982, Intracerebral adoptive immunotherapy of a murine lymphoma antigenically altered by drug treatment in vivo.Journal of National Cancer Institute,68, 817–822.Google Scholar
  24. [24]
    Romani, L., Nardelli, B., Bianchi, R., Puccetti, P., Mage, M., andFioretti, M. C., 1985, Adoptive immunotherapy of intracerebral murine lymphomas: role of different lymphoid populations.International Journal of Cancer,35, 659–665.Google Scholar
  25. [25]
    Sava, G., Giraldi, T., Lassiani, L., andNisi, C., 1979, Mechanism of the antimetastatic action of dimethyltriazenes.Cancer Treatment Reports,63, 93–98.Google Scholar
  26. [26]
    Schirrmacher, V., 1985, Cancer metastasis: experimental approaches, theoretical concepts, and impacts for treatment strategies.Advances in Cancer Research,43, 1–73.Google Scholar

Copyright information

© Taylor & Francis Ltd. 1989

Authors and Affiliations

  • M. Allegrucci
    • 1
  • P. Fuschiotti
    • 1
  • P. Puccetti
    • 1
  • L. Romani
    • 1
  • M. C. Fioretti
    • 1
  1. 1.Institute of PharmacologyUniversity of PerugiaPerugiaItaly

Personalised recommendations